Chapter 70: Drugs for Obesity

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine your car's gas tank is completely full, like overflowing actually,

but the fuel gauge on the dashboard is screaming empty.

Right, the warning light is flashing.

Exactly, the alarm is dinging.

So you just keep frantically pulling over to buy more gas.

Well, that physiological trick, that exact scenario, is essentially what happens in the brain of a patient struggling with obesity.

It really is.

So welcome to today's deep dive.

If you're joining us, we're basically acting as your personal study buddy today.

We are going straight into the textbook, specifically focusing on chapter 70 from Len's Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants, the third edition.

And we were specifically looking at the drugs for obesity chapter.

Right, and our mission today is to unpack all of this for you so that you can make safe, evidence -based clinical decisions.

Because understanding that broken fuel gauge concept,

it's absolutely critical before you even think about writing a prescription.

I mean, when you look at the statistics in the text, they paint a pretty staggering picture of public health.

Oh, duh.

In the United States alone,

70 .7 % of adults are overweight.

And within that massive group, 39 .8 % are categorized as obese.

Okay, let's unpack this.

Because to actually treat a patient, we first have to figure out their actual risk level, right?

Exactly.

We need to systematically walk you through the text in its exact order, from assessment and pathophysiology to treatment algorithms, and then the specific pharmacology.

Right, so let's start with assessment.

The text lays out three main pillars of weight -related health risk assessment.

The first one is the classic body mass index, or BMI.

The standard metric.

Yeah, underweight is less than 18 .5.

Normal is up to 24 .9.

Overweight sits between 25 and 29 .9.

And then obese jumps to the 30 to 39 .9 range.

Severely obese is anything 40 and above.

But, I don't know, BMI always feels like just a rough sketch of a patient to me.

Well, it is a rough sketch.

It's simply a calculation of height and weight.

It does not tell you where that adipose tissue is actually located.

Which is important.

Extremely.

That is why the second pillar of assessment is waist circumference.

This measurement targets abdominal fat, which is highly metabolically active.

Meaning it causes issues.

Right, it releases inflammatory mediators and significantly increases the risk for insulin resistance, hypertension, and cardiovascular disease.

So, the high -risk thresholds to memorize are a waist circumference greater than 40 inches for men and greater than 35 inches for women.

So it's really zooming in on the danger zone, but there's a caveat in the text about who we actually measure, right?

Yes,

a vital clinical caveat.

Waist circumference is primarily an indicator of increased risk for patients who have a BMI between 25 and 34 .9.

Oh, so just that middle group.

Exactly.

If a patient's BMI is already over 35, you already know their risk is exceptionally high.

The waist measurement won't change your clinical management at that point.

Got it.

Which brings us to the third pillar, risk status.

This is where you look at the patient's entire chart for cardiovascular risk factors and obesity -related diseases.

Things like type 2 diabetes mellitus or sleep apnea.

Right, so you take the BMI sketch, the waist circumference focus, and the overall disease risk to get a complete picture.

But the burning question is, how does a patient get to this point?

Because the old stigma of they just eat too much, that's completely outdated.

It's a profound clinical misconception.

The text explicitly defines obesity as a chronic disease.

It is driven by a complex neuroendocrine system, genetics, and even the gut microbiome.

Wow, even the microbiome.

Consider the FTO gene variant mentioned in the chapter.

This variant alone is estimated to cause up to 15 to 20 % of obesity cases.

It literally alters the fat cells so they store more energy than they expend.

That's wild.

And on top of that, you have hypothalamic dysregulation, where the neurons in the brain responsible for orchestrating nutrient utilization basically misfire.

And this brings us right back to that broken fuel gauge analogy.

A huge part of that misfiring comes down to a hormonal tug of war between two main players, Grelin and Leptin.

The big two.

Yeah, so Grelin is the appetite stimulant made in the stomach.

Stomach empties, Grelin spikes, brain says, eat.

You eat, it drops.

Leptin is the opposite.

It's the appetite suppressant, and it's actually produced by the fat cells themselves.

Which, in theory, should create a perfect, self -regulating physiological feedback loop.

As fat mass increases, leptin production increases.

That leptin travels to the brain to signal that the body has plenty of energy stored, which should promote satiety.

But wait, if more fat equals more leptin, shouldn't people with obesity feel less hungry?

Like, they should feel completely full all the time.

You would think so.

But that is the paradox of leptin resistance.

The fat cells are pumping out leptin.

The gas tank is entirely full.

But the brain's receptors have become resistant to the signal.

So the gauge reads empty.

Exactly.

The brain literally thinks the body is starving, despite massive energy reserves.

And if you were trying to help a patient lose weight, you have to understand how devastating this is for maintenance.

Because what happens when they actually diet?

When a patient diets and loses weight, their fat cells shrink.

Leptin levels instantly plummet, completely removing that already weak feeling of satiety.

Oh no.

And simultaneously, their Grelin levels rise.

Their own physiology is screaming at them to regain the lost weight.

If the body is fighting back that aggressively, just telling a patient to go on a diet is pretty terrible medical advice.

I mean, we clearly need a structured approach.

And a massive takeaway from the text here is that the clinical goal of treatment is not reaching a normal BMI.

Right.

That is a critical point for patient education.

Attempting to reach a normal BMI often sets patients up for perceived failure.

The clinical goal, according to the evidence, is a 10 to 15 % reduction in body weight.

Just 10 to 15%.

Sustaining that specific percentage is enough to dramatically decrease cardiovascular risk and prevent obesity -related comorbidities.

So how do we actually get them to that 10 to 15 % drop?

Box 70 .1 in the text lays out lifestyle therapy, which is the foundation of everything.

It involves a balanced portion -controlled diet, of course.

But the exercise metrics really caught my eye.

Oh, the aerobic requirements.

Yeah.

To lose weight, patients need at least 150 minutes of aerobic exercise per week.

But to maintain that weight loss, they need 200 to 300 minutes a week.

The maintenance phase actually requires more work than the initial loss.

And that goes right back to the plumping leptin and rising ghrelin.

The body becomes more metabolically efficient at holding onto calories after weight loss.

So you have to work harder just to stay at the new baseline.

That is so frustrating for patients.

It is.

So to help clinicians navigate when lifestyle therapy isn't enough, the text provides the AAC ACE clinical algorithm.

Figure 70 .3 visualizes this decision -making process into distinct stages.

Let's break that algorithm down for you.

If you are looking at a patient's chart, how do you categorize them?

Well, you start at stage zero.

This is a patient with a BMI of 25 or more, but no obesity -related complications.

Here, lifestyle therapy is your primary and usually only intervention.

So no drugs yet.

No.

You only consider pharmacotherapy if lifestyle changes alone prove completely ineffective over time.

Then you step up to stage one.

This is still a BMI of 25 or more, but now you are seeing mild to moderate complications in their labs or exams.

Right.

You keep pushing the lifestyle therapy, but if their BMI is 27 or higher, you strongly consider adding weight loss drugs.

Got it.

And stage two.

Stage two is a BMI of 25 or more with severe complications.

Here, drug therapy is explicitly indicated for anyone with a BMI of 27 or more.

And if the patient reaches a BMI of 35 or more, bariatric surgery should be evaluated.

I want to pause on bariatric surgery and devices for a second.

Bariatric surgery is obviously highly effective, but it's intense.

I mean, the text notes a one -year mortality risk of up to 4 .6 % after gastric surgery.

Is a major procedure.

Right.

But then on the other end of the spectrum, you have non -drug devices like Plenity or Gelasis.

This is wild to me.

It's an oral super absorbent hydrogel.

The patient swallows three capsules with 16 ounces of water before a meal.

Correct.

It is technically a medical device, not a systemic drug.

It expands in the stomach and small intestine to physically take up space, creating a mechanical feeling of fullness.

It's basically like swallowing a tiny sponge that blows up inside you.

But if you have a massive sponge in your gut, won't that mess with everything else you swallow?

Yes, and that requires rigorous patient education.

Because it acts like a sponge, it can block or delay the absorption of other medications.

Oh, what's the rule?

If you have a patient using Plenity, they must take their oral medications at least one hour before or two hours after the device to ensure their other therapies aren't compromised.

All right, so when the lifestyle changes and the gut sponges aren't enough, we enter the world of pharmacotherapy.

But before we prescribe a single pill or injection, the text gives us a hard and fast general rule for evaluating if a drug is actually working.

The four -week rule.

Patients must be evaluated regularly.

They should lose at least four pounds in the first four weeks of drug treatment.

Four pounds, four weeks.

Exactly.

If they fail to meet that baseline, the drug is likely not effective for their specific physiology.

You have to reassess their adherence or consider discontinuing the medication entirely to avoid exposing them to side effects for no clinical benefit.

Let's look at those side effects.

Starting with the lipase inhibitors.

The prototype drug here is Orlistad.

You might see it over the counter as Alli or by prescription as Zeneca.

Right.

The mechanism of action here is completely different from everything else in the chapter.

It doesn't touch the brain.

It acts locally in the stomach and small intestine by irreversibly inhibiting gastric and pancreatic lipases.

Yes, and lipases are the enzymes responsible for breaking down dietary triglycerides into absorbable free fatty acids.

By inhibiting them, Orlistad effectively blocks about 30 % of dietary fat from being absorbed.

It just remains in the digestive tract.

It's like a bouncer at a club just standing at the intestinal wall and kicking 30 % of the fat straight to the exit.

But that sounds like a very messy exit.

It is extremely poorly tolerated by many patients.

In fact, clinical guidelines from the American Gastroenterological Association, the AGA, do not recommend Orlistad.

Wait, really?

They don't recommend it at all.

No.

When you weigh its relatively small clinical benefit, an average weight loss of only 2 .78 % of total body weight against its adverse effects,

the profile is just unfavorable.

Because of the GI issues.

Exactly.

Because that unobsorbed fat remains in the gut, 20 to 30 % of patients experience oily rectal leakage,

flatulence with discharge, and severe fecal urgency.

Yeah, you can totally see why patients would abandon that drug immediately.

But if a patient is determined to use it, or it's like their only option, how do you clinically manage those gastrointestinal nightmares?

What's fascinating here is a pharmacological workaround.

Dosing the patient with psyllium, a bulk -forming laxative like Metamucil, can significantly mitigate these issues.

Oh, that makes sense.

Yeah, the psyllium physically absorbs the unobsorbed dietary fat within the gut lumen, reducing the leakage and urgency.

That is a brilliant clinical pearl.

But you also have to worry about drug and nutrient interactions, right?

Because if it's blocking fat, it's blocking anything that dissolves in fat.

Orlistat decreases the absorption of fat -soluble vitamins, A, D, E, and K.

Patient education must include taking a daily multivitamin, and they have to space it at least two hours apart from the Orlistat dose.

Any other drug spacing?

Yes.

You also have to space cyclosporine by three hours, and levothyroxine by four hours.

And there is a major warning about warfarin in the text.

Since vitamin K is essential for blood clotting, an Orlistat -induced vitamin K deficiency can dangerously intensify warfarin's anticoagulant effects, leading to severe bleeding.

You really have to watch those patients closely.

Absolutely.

Now, let's move away from the gut and into the brain.

The second class of drugs are the sympathomimetic amines, specifically diethylpropion and fentermime.

These agents work directly on the central nervous system.

They are systemic stimulants that increase the availability of norepinephrine in the brain, which powerfully suppresses appetite.

But I have to push back on the clinical logic here.

We established at the top of the show that obesity is a lifelong chronic disease, yet the text explicitly states these sympathomimetics are only approved for short -term use, meaning less than three months.

That's right.

So why use a short -term tool for a lifelong problem?

This raises an important question about the limitations of older pharmacology.

The short -term restriction is strictly due to physiological tolerance.

The appetite -suppressing effects usually plateau and diminish within six to 12 weeks.

Ah, so they just stop working.

Yes.

Furthermore, because they are amphetamine -like stimulants, they carry a real potential for abuse and dependence.

They are schedule -four controlled substances.

And because they are jacking up norepinephrine, the adverse effects are basically a constant adrenaline rush.

You are looking at tachycardia, hypertension, and insomnia, which is why you tell the patient to take their last dose before 4 p .m., otherwise they'll be staring at the ceiling all night.

And those systemic effects dictate strict contraindications.

You cannot give these to patients with cardiovascular disease, hyperthyroidism, or glaucoma.

Makes sense.

Furthermore, there's a severe, life -threatening drug interaction.

They must never be taken within two weeks of a monoamine oxidase inhibitor, an MAOI, because the combined surge in norepinephrine can trigger a fatal hypertensive crisis.

So if sympathomimetics tap out after three months, what do we do for year two or year five of a patient's treatment?

Clinicians need long -term tools.

And that's where the glucagon -like peptide -1 or GLP -1 receptor agonists come in.

They are very prominent right now.

Yeah, these drugs are everywhere.

They started as diabetes medications, but the weight -loss side effect was so profound they gained approval for obesity.

The three major players highlighted in the text are allureglutide, branded as Saxenda, which is a daily subcutaneous injection.

Then there is semiglutide, or WIGOVI, given weekly, and the newest iteration, terzepatide or ZepBound, which is actually a dual -action GIP and GLP -1 agonist, also given weekly.

I know they are incredibly popular, but how do they actually work to drop the weight so effectively?

Their mechanism is twofold.

Peripherally, they dramatically slow gastric emptying.

Food physically remains in the stomach for a much longer period.

Centrally, they cross into the brain and act on the hypothalamus to promote a profound, lasting sense of fullness.

So they hit the gut and the brain.

Exactly.

The AGA highly recommends GLP -1 agonists for long -term use because they offer moderate to large weight loss with a remarkably low risk of serious, systemic adverse effects compared to older drugs.

So what does this all mean for the patient taking the injection?

Like, what's the day -to -day reality?

Because their stomach isn't emptying normally, the side effects are overwhelmingly gastrointestinal.

Yes, very common.

Nausea, vomiting, and dyspexia are almost expected, especially when titrating the dose up.

You also have a risk for hypoglycemia, but usually only if the patient is already taking other anti -diabetic medications.

Oh, and you often see a notable increase in resting heart rate, sometimes 10 to 20 beats per minute over their baseline.

While those are the daily annoyances, we absolutely most emphasize the black box warning associated with this class.

It is a critical safety alert that every prescriber must know.

What is it?

In rodent studies, liraglutide and other GLP -1s have been associated with an increased risk of thyroid C -cell tumors.

Wow, that is terrifying.

How do we screen for that clinically?

Because of that risk, these drugs are absolutely contraindicated in patients with multiple endocrine neoplasia syndrome, type 2, and main N2, or anyone with a personal or family history of medullary thyroid carcinoma, MTC.

You must take a thorough family history before initiating therapy.

Okay, let's look at the final category of drugs.

Sometimes, to outsmart the body's adaptations, we need to hit multiple pathways at once.

There are two long -term combination products approved by the FDA that do exactly this.

The first one is Fenermine and Topiramate, sold under the brand name Cuthymia.

Now, we already know Fenermine is a stimulant that suppresses the appetite, but Topiramate is usually a seizure or migraine medication.

Why is it in a weight loss pill?

Topiramate induces a sense of satiety, but its mechanism is complex.

It involves GABA modulation and antagonism of glutamate.

Wait, unpack that for us.

What does that actually mean for the patient's brain?

Think of GABA as the brain's primary inhibitory neurotransmitter, the chill -out chemical.

Glutamate is the primary excitatory neurotransmitter, the go chemical.

By enhancing GABA and blocking glutamate, Topiramate basically turns down the volume on the brain's drive to eat and turns up the brakes, creating a powerful chemically -induced feeling of being satisfied.

That makes a lot of sense, but the monitoring for Cuthymia is very specific.

You don't just write the script and see them in a year.

You must evaluate the patient after 12 weeks on the maintenance dose.

If they haven't lost at least 5 % of their baseline body weight by that 12 -week mark, you have to taper them off.

And tapering is essential, because abruptly stopping to Pyrimate can trigger seizures.

The adverse effects profile for Cuthymia is hefty.

You have the cardiovascular risks from the phantrum end, but the Topiramate adds neurological issues.

Patients frequently complain of memory impairment, word -finding difficulties, and trouble concentrating.

Most importantly, Topiramate is highly teratogenic.

It causes severe birth defects like cleft lip and palate.

That is a massive lifespan contraindication.

Huge.

It is also contraindicated in glaucoma and hyperthyroidism.

And again, you need that two -week gap if they've been on an MAOI.

Okay, so the second combination product is Naltrexone and Bupropion, known as Contrav.

This drug targets an entirely different system.

It bypasses the stomach and goes straight for the mesolimbic dopamine system and the hypothalamus.

The mesolimbic dopamine system is the brain's primary reward pathway.

When a patient eats highly palatable calorie -dense foods, this pathway floods with dopamine, reinforcing the behavior.

Food addiction, basically.

Exactly.

By modulating this pathway, Contra helps diminish the intense cravings and the chemical reward associated with food addiction.

It essentially cuts the joy out of overeating.

But this drug comes with an incredibly severe black box warning.

Because it contains Bupropion, which is an antidepressant, it carries the standard antidepressant warning for severe neuropsychiatric reactions.

That's right.

We are talking about an increased risk of suicidal ideation and suicide attempts, specifically in children, adolescents, and young adults.

That requires rigorous, ongoing psychological monitoring.

Furthermore, its contraindications are extensive.

Because Bupropion lowers the seizure threshold,

Contrav should never be used in patients with seizure disorders.

Or eating disorders.

Correct.

No anorexia or bulimia, or patients undergoing acute withdrawal from alcohol or benzodiazepines.

It is also contraindicated in uncontrolled hypertension.

And here is a huge clinical trap that could happen in the ER.

Contrav contains naltrexone, which is an opioid antagonist.

If your patient is on this weight -loss drug, gets into a car accident, and needs opioid pain relief in the emergency room, the naltrexone will literally block the opioids from working.

It's a critical interaction to be aware of.

You also have to consider the pharmacokinetics.

Eupropion is heavily metabolized by the CYP2B6 enzyme pathway in the liver.

So think of that CYP pathway like a conveyor belt in the liver's processing plant.

If you give Contrav alongside another drug that inhibits or induces that conveyor belt, you are going to drastically alter the drug levels in the patient's blood.

It could lead to toxic buildup or subtherapeutic failure.

To wrap up our pharmacology review, we need to apply these drugs across the lifespan, as outlined in the text's lifespan table.

The big rules.

Yes.

The absolute non -negotiable rule of thumb, none of these weight -loss drugs are recommended during pregnancy.

The risks to the fetus far outweigh any maternal weight -loss benefits.

Breastfeeding is also generally not recommended while on these agents.

And if you are treating pediatric patients, your toolbox shrinks dramatically, the combination drugs are out, disalpropion and fentermine are absolutely not recommended for anyone under 16.

So what's left?

Well, if you have a pediatric patient struggling with obesity, the only FDA -approved pharmacological options you have are semaglutide, liraglutide, and prescription oralistat, specifically the zenical dosing, and even then, only for those 12 years and older.

Which brings us to a vital concluding thought pulled directly from the text itself.

It is a sobering note for any prescriber.

Historically, weight -loss drugs have a very dark and disturbing track record.

They really do.

Think of fenfen or subutramine.

These drugs frequently receive FDA approval, see massive widespread use in the population, and then are suddenly pulled off the market years later due to post -marketing discoveries of severe, sometimes fatal adverse effects like valvular heart disease or strokes.

It's a sobering reminder that FDA approval is just the beginning of a drug safety story, not the end.

You have to remain ever vigilant, keep up with the current literature, monitor your patients closely, and never assume a drug is entirely risk -free just because it's popular in the media right now.

Absolutely.

We are fighting ancient, deeply ingrained physiological systems that want to keep that gas tank full.

It takes precision, patience, and an unwavering commitment to safety to help a patient navigate that.

So thank you so much for joining us for this deep dive into Chapter 70.

The session was brought to you by the Last Minute Lecture Team, wishing you the best of luck in your studies and your clinical practice.